Arvinas is a biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTACTM protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell’s own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.
Building on groundbreaking research at Yale University by Craig Crews, Ph.D., Arvinas’ Founder and Chief Scientific Advisor, Arvinas has developed a broad technology platform focused on high-value targets, with the potential to deliver safer, more potent treatment than small molecule inhibitors, and to address up to 80% of proteins that evade inhibition and are currently undruggable.
The Company’s therapeutic development is initially focused on developing degraders for high-value targets in cancer, including the androgen and estrogen receptors. We have significant collaborations with Pfizer and Genentech to leverage our PROTAC® technology platform for additional targets, and are funded by leading venture capital firms in the biotechnology sector.